Jones Hill Capital
Jones Hill Capital reported 33 stocks worth $589M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are BMRN (11.9%), BCRX (10.0%) and TVTX (9.6%). Compared with Q2 2026, the fund opened new positions in BCRX, TVTX and INDV, added to PHVS, TRVI and BCAX, trimmed BMRN, INSM and IMCR and sold out of GILD, ARQT and MDGL.
Latest filing: what Jones Hill Capital did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() BMRN Biomarin Pharmaceutical Inc | $70.3M | 11.9% | 1.2M | −260K (−18%) | 3 of 3 | |
| 2 | ![]() BCRX Biocryst Pharmaceuticals Inc | $59M | 10.0% | 7.1M | New position | 1 of 3 | |
| 3 | ![]() TVTX Travere Therapeutics Inc | $56.5M | 9.6% | 960K | New position | 1 of 3 | |
| 4 | ![]() INDV Indivior PLC | $54.7M | 9.3% | 1.5M | New position | 1 of 3 | |
| 5 | ![]() PHVS Pharvaris N V | $31.3M | 5.3% | 988K | +310K (+46%) | 3 of 3 | |
| 6 | ![]() CELC Celcuity Inc | $30.4M | 5.2% | 383K | New position | 1 of 3 | |
| 7 | ![]() IONS Ionis Pharmaceuticals Inc | $26.8M | 4.5% | 600K | New position | 1 of 3 | |
| 8 | ![]() SUPN Supernus Pharmaceuticals Inc | $25.9M | 4.4% | 602K | New position | 1 of 3 | |
| 9 | ![]() NUVB Nuvation Bio Inc | $25.1M | 4.3% | 4.5M | New position | 2 of 3 | |
| 10 | ![]() VERA Vera Therapeutics Inc | $21.1M | 3.6% | 652K | New position | 1 of 3 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() GILD Gilead Sciences Inc | $43.3M | 343K |
![]() ARQT Arcutis Biotherapeutics Inc | $28.6M | 1.1M |
![]() MDGL Madrigal Pharmaceuticals Inc | $28.2M | 53K |
![]() XENE Xenon Pharmaceuticals Inc | $22.2M | 368K |
![]() ANIP Ani Pharmaceuticals Inc | $19.4M | 234K |
🔒 Free account: see all 15.
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Jones Hill Capital 13F FAQ
What does Jones Hill Capital own?
Jones Hill Capital reported 33 stocks worth $589M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are BMRN (11.9%), BCRX (10.0%) and TVTX (9.6%). The table above lists every position in the filing (the top 10 without an account).
What did Jones Hill Capital buy and sell in Q3 2026?
Compared with Q2 2026: 19 new positions, 9 added to, 5 trimmed and 15 sold out. New positions include BCRX, TVTX and INDV. It sold all of GILD, ARQT and MDGL.
When will Jones Hill Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Jones Hill Capital's portfolio worth?
The Q3 2026 filing reports $589M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.






















